Different groups with co-morbid characteristics were analyzed separately to find out association with the comorbidity.
Comparative analysis of ADHD probands subgrouped on the basis of co-morbid characteristics revealed the following observations.
Possible sources include differences between the demographic and co-morbid characteristics of the populations studied and the different follow-up periods in the prospective studies.
We compared baseline demographic, gout and co-morbid characteristics, ULE, and safety of XOI treatment in diabetic and non-diabetic gout patients.
Baseline clinical, demographic and co-morbid characteristics of women and men were compared using chi-square analysis for the categorical variables and students t-test for continuous variables.
Table 3 presents adjusted odds ratios (AOR) for the utilization outcomes based on the timing of Physical Therapy, which were obtained from logistic regression models that adjusted all demographic and baseline co-morbid characteristics listed in Table 1.
Adjusting for the demographic and baseline co-morbid characteristics, the odds ratios for health services utilized during the 2-year follow-up period based on adherence to LBP practice guidelines are detailed in Table 3.
Prognostic factors, such as demographic, diagnostic or co-morbid characteristics of an individual measured at baseline, are generally used to identify those with a greater likelihood of a poor outcome over time [ 12, 13].
Since numbers of cases were small after stratification based on co-morbid characteristics, for this analysis, we have used the haplotype-based haplotype relative risk (HHRR) program under the UNPHASED; transmission from informative as well as noninformative parents is taken into account for HHRR [ 37].
Among different co-morbid characteristics, oppositional defiant disorder (ODD), conduct disorder (CD), anxiety disorder (AD), depressive disorder, mood disorder (MD), and learning disabilities (LD) are of frequent occurrence [ 2]; around 27% of ADHD patients were reported to have ODD and/or CD, while 18% had AD.
A large dataset gathered in a previously reported randomized, double-blind trial comparing urate-lowering treatment with febuxostat or allopurinol 25 afforded the opportunity for post-hoc comparisons of diabetic and non-diabetic gout patients with regard to: baseline demographic, gout-related and co-morbid characteristics; and urate-lowering effectiveness and tolerability of XOIs.
